BITT secures NIH funding for pioneering Sjögren’s syndrome treatment
Boston Immune Technologies and Therapeutics, Inc. (BITT), a leading clinical-stage biotechnology firm specializing in tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, has received a ... Read More
FDA greenlights BITT’s Phase I trial of BITT2101 for Non-Hodgkin’s lymphomas
Boston Immune Technologies and Therapeutics, Inc. (BITT), a pioneering clinical-stage biotech company, has announced the US Food and Drug Administration's (FDA) clearance for the Investigational ... Read More